Rasagiline Mesylate Tablets Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast - 2022 to 2028

The global rasagiline mesylate tablets market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Rasagiline mesylate tablets are used for the treatment of several symptoms of Parkinson's disease including shakiness, stiffness, and difficulty in moving. The major factor attributing to the growth of the global rasagiline mesylate tablets market includesthe risingprevalence of Parkinson's disease across the globe. According to the statistics published by the Parkinson's Foundation, around 10 million people wereliving with Parkinson's disease across the globein 2020. Among these, around 1 million Parkinson's disease cases are all diagnosed in the USalone, which is more than the combined number of multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease. This numbersare furtherexpected to rise to 1.2 million cases by 2030. The chances of getting affected by Parkinson's disease increase with age and it is estimated that around 60,000 people are diagnosed with Parkinson's disease every year in the USalone. Rasagiline mesylate tablets are beneficial in the treatment of Parkinson's disease by certain natural substances levels in the brain. These substances include dopamine, norepinephrine, and serotonin.

A full report of Rasagiline Mesylate Tablets Market is available at:https://orionmarketreports.com/rasagiline-mesylate-tablets-market/104380/  

In addition, new developments are also contributing to the growth of the market. For instance, in May 2021, a study titled "Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: in-vitro and in-vivo assessment for Parkinson's therapy" was published by the European Journal of Pharmaceutics and Biopharmaceutics. This study describes the new formulation of rasagiline for the treatment of Parkinson's disease that can be applied to the skin. Due to the challenges of the inconsistent amount of medications reaching the brain during the oral route of administration, researchers created a new formulation of rasagiline that can be delivered by the transdermal route of administration. It can be directly applied to the skin and then absorbed into the body in the treatment therapy of Parkinson's disease.

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Distribution Channel
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World
Competitive Landscape- Teva Pharmaceuticals Industries Ltd., Viatris Inc., Apotex Inc., Novartis International AG, andSun Pharmaceuticals Ltd., among others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Rasagiline Mesylate Tablets Market Report by Segment

By Distribution Channel

Hospital Pharmacies
Retail Drug Stores

 Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.